Nanotechnology-Based Detection and Cancer Theranostics
A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Point-of-Care Diagnostics and Devices".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 236
Special Issue Editor
Interests: nanomedicine; nanoparticle; biological and medicinal chemistry, cell toxicity; CT; MRI; magnetic particle imaging (MPI); drug delivery; cancer diagnosis; photodynamic therapy (PDT); photothermal therapy (PTT); chemodynamic therapy (CDT); ultrasound therapy; cancer therapy; tumor therapy; stem cell therapy
Special Issue Information
Dear Colleagues,
Compared to traditional small-molecule therapeutic drugs, nanomedicines, which include metal nanoparticles, inorganic nanoparticles, metal-organic frameworks, polymer nanoparticles, and exosomal nanoparticles, among others, offer a plethora of unique advantages in both the diagnosis and treatment of cancer. These advantages encompass a wide array of capabilities, such as the Enhanced Permeability and Retention (EPR) effect, drug protection, sustained drug release, the ability to surmount biological barriers, precise targeted delivery, enhanced solubility, and biocompatibility, as well as the ability to overcome drug resistance and facilitate the delivery of multiple drugs simultaneously. Nanomedicines also tap into the intricacies of the tumor microenvironment, possess immunoevasive properties, enable triggered activation, boast a large specific surface area, and exhibit distinctive electromagnetic properties. Moreover, they lend themselves effectively to combination diagnostics and therapy and the burgeoning field of theragnostics, which showcases their multifunctional nature.
The harnessing of these formidable advantages undoubtedly has the potential to revolutionize cancer diagnosis and treatment, leaving a profound impact on the field. This Special Issue is dedicated to aggregating the latest and most cutting-edge research that exploits the capabilities of nanomedicines in the domain of detection and cancer treatment, with a special emphasis on their unique advantages (compared with traditional medicines) in detection and theranostics for cancer.
Dr. Chao Wang
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- nanotechnology
- detection
- multifunctional nanoplatform
- cancer
- nanomedicine
- tumor
- theranostics
- EPR effect
